CUV has the only current approved if not only treatment for the skin disorder so it warrants a premium PE. How much, well Ill let individual investors determine that.
They also have the cash in the bank to rollout Scenesse in the US without having to search for funds so its lets hit the road full speed ahead. They were ready for this, so delays will be minimal.
News: CUV UPDATE 1-U.S. FDA approves Clinuvel Pharma's rare genetic disorder treatment, page-56
-
- There are more pages in this discussion • 66 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.72 |
Change
-0.100(0.67%) |
Mkt cap ! $737.1M | |||
| Open | High | Low | Value | Volume |
| $14.80 | $14.97 | $14.60 | $600.3K | 40.64K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 324 | $14.69 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.75 | 100 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| CUV (ASX) Chart |